Evidence map›Paper›PMID 40951707›Full record

ArticleWorld journal of stem cells2025

Expression of stem cell marker musashi-1 and its relationship with survival prognosis in patients with resectable esophageal squamous cell carcinoma.

Ya-Xuan Niu, Min Hu, Wei-Feng Zhao, Hong-Jie Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ya-Xuan NiuDepartment of Laboratory, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450000, Henan Province, China. mini209@126.com.
Min HuDepartment of Laboratory, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450000, Henan Province, China.
Wei-Feng ZhaoTumor Center, Henan Provincial People's Hospital, Zhengzhou 450000, Henan Province, China.
Hong-Jie YangTumor Center, Henan Provincial People's Hospital, Zhengzhou 450000, Henan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors globally, with its incidence particularly high in East Asia.

aimTo analyze the expression of the stem cell marker musashi-1 in patients with resectable ESCC undergoing neoadjuvant chemotherapy and its relationship with patient survival prognosis.

methodsA retrospective analysis was conducted on the clinical data of 74 ESCC patients treated at our hospital from June 2020 to January 2022. All patients received neoadjuvant chemotherapy and surgical resection. Immunohistochemistry (IHC) was used to detect musashi-1 expression in tumor tissues. Based on the expression intensity, patients were divided into group A (

resultsThere were statistically significant differences in tumor maximum diameter, T stage, N stage, clinical stage, pathological grade, lymphovascular invasion, and intraoperative blood loss between groups A and B (

conclusionThe expression of musashi-1 is closely related to the treatment efficacy, prognosis, and survival of ESCC patients. It is expected to be a potential biomarker for evaluating the efficacy and survival prognosis of ESCC patients.

Indexed as

Musashi-1Neoadjuvant chemotherapyResectable esophageal squamous cell carcinomaStem cell markerSurvival prognosis

Identifiers

PMID40951707
PMCPMC12427057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.